Claims for Patent: 8,877,443

Summary for Patent: 8,877,443

Title:	Method and kit for evaluation of predisposition to development of obesity, anti-obesity agent and method for screening thereof, non-human animal, adipose tissue, adipocyte, method for production of transgenic mouse, antigen, and antibody
Abstract:	It is an object of the present invention to provide a method of evaluating whether or not a subject has a predisposition to obesity or an obesity-related condition or disease, a kit for conducting the method, an anti-obesity drug having an effect of preventing or treating obesity or an obesity-related condition or disease, a method of screening the anti-obesity drug, a non-human animal having a deficiency in the gene associated with obesity, and an adipose tissue or adipocyte of the animal. The method of evaluating a predisposition to obesity of the present invention is a method of evaluating whether or not a subject has a predisposition to obesity or an obesity-related condition or disease. The method includes the step of detecting a copy number variation (CNV) in intron 1 of SLC25A24 gene or a gene polymorphism having a linkage disequilibrium relationship with the CNV in a sample containing a human gene of the subject. If the CNV in intron 1 of the SLC25A24 gene is 0, the subject may be evaluated to have a predisposition to obesity or an obesity-related condition or disease.
Inventor(s):	Inoue; Satoshi (Tokyo, JP), Urano; Tomohiko (Tokyo, JP), Ouchi; Yasuyoshi (Tokyo, JP), Shiraki; Masataka (Nagano, JP)
Assignee:	The University of Tokyo (Tokyo, JP)
Application Number:	13/320,674
Patent Claims:	1. A method for diagnosing susceptibility to increased body fat after menopause in a female subject, the method comprising: collecting gDNA from the subject; measuring the copy number of the sequence of 108534690-108535300 on chromosome 1 from intron 1 of SLC25A24 gene in the gDNA of the subject, wherein the sequence is measured by a TaqMan PCR method; detecting a copy number of zero for the sequence of 108534690-108535300 on chromosome 1 from intron 1 of SLC25A24 gene in the subject; and diagnosing the subject with a zero copy number of the sequence as more susceptible to increased body fat after menopause compared to female subjects having one or more copy number(s) of the sequence.

Details for Patent 8,877,443

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2029-05-15
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2029-05-15
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2029-05-15